200780.Kq

The company's capital structure is characterized by a high debt-to-equity ratio of 1.22, indicating a significant reliance on debt financing. With total liabilities of KRW 105.52 billion and total equity of KRW 71.28 billion, the firm's leverage is above the typical thresholds for the pharmaceutical industry. Liquidity is constrained, as evidenced by a current ratio of 0.55, and the firm holds only KRW 5.88 billion in cash and equivalents, which is insufficient to cover its short-term obligations. The negative net cash position, after subtracting total debt, further highlights the company's liquidity challenges.

Profitability metrics are weak, with a return on equity (ROE) of -6.87% and a return on assets (ROA) of -2.77%. These figures are below the industry median for both metrics, indicating underperformance relative to peers. The company reported a net loss of KRW 4.90 billion, despite generating KRW 30.59 billion in gross profit, suggesting high operating expenses or one-time charges. The operating margin is also likely below the industry average, given the low operating income of KRW 1.99 billion on total revenue of KRW 75.80 billion.

The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the firm's exposure is not disclosed, but the lack of diversification increases vulnerability to market-specific risks. The absence of segmental or geographic detail limits the ability to assess the firm's strategic positioning or potential for growth in emerging markets.

The company's growth trajectory is uncertain, as no forward-looking revenue guidance is provided. Historical revenue of KRW 75.80 billion does not indicate a clear upward or downward trend. The firm's capital expenditures of KRW 4.01 billion suggest ongoing investment in infrastructure or R&D, but the negative free cash flow of KRW 800.63 million indicates that these investments are not yet generating sufficient returns. The outlook for the next fiscal year remains unclear without additional data on product pipelines or market expansion plans.

The company faces moderate liquidity risk due to its high debt load and weak cash position. The risk assessment flags a negative net cash position after subtracting total debt, which could limit the firm's ability to meet obligations or fund operations without external financing. Dilution risk is currently low, as the number of shares outstanding has not changed between basic and diluted shares. However, the firm may need to issue additional shares in the future to raise capital, which could dilute existing shareholders.

Recent financial filings show a net loss for the period, despite positive operating cash flow of KRW 5.58 billion. This discrepancy may be due to non-cash expenses or changes in working capital. No recent earnings call transcripts or press releases are available to provide further insight into the firm's strategic direction or operational performance.